About ZyCoV-D^®

ZyCoV-D^® is the world’s first plasmid DNA vaccine for human use that has been developed in India and given restricted use license for emergency situation.^1-3

ZyCoV-D^® is indicated for active immunisation of individuals ≥12 years old for the prevention of coronavirus disease 2019 (COVID-19). ZyCoV-D^® vaccination schedule consists of 3 separate doses to be given at an interval of 28 days each (day 0, day 28 and day 56). Each dose consists of two shots of 0.1ml each given by needle free injector (PharmaJet Tropis device) via intradermal route at two separate sites (preferably deltoid region of both the arms). The vaccine should be stored at temperatures ranging from 2° to 8°C and should never be frozen.⁴

ZyCoV-D^® Trivia

Results of the clinical trials have been
generated during the peak of the
pandemic, establishing the efficacy of
ZyCoV-D^® against dominant strains in
circulation (Delta, Beta and other variants)^{5, 7}

World’s first plasmid DNA vaccine
for COVID-19¹

Minimum biosafety requirement for
manufacturing^6,12

Atmanirbhar Bharat: Indigenously
researched and developed pDNA Vaccine
made in India, for India after following
stringent global safety protocols

First vaccine in India to be approved
for individuals aged 12 years and
above ⁴

Clinically tested in one of the largest
randomized clinical trials of any
indigenously developed COVID-19
vaccine, enrolling approx. 30,000
subjects across India^{5, 6}

Administered via an innovative
Needle-Free Injection System (NFIS)
using PharmaJet Tropis
device⁴

Demonstrated efficacy of 66.6% for
symptomatic and 100% for moderate
and severe COVID-19 cases⁷

Efficient large-scale, low-cost
production and storage capabilities
at 2-8°C

Generates strong immune response,
including both cellular and humoral
immunity⁸

It can be quickly adapted to manufacture
vaccine against new mutant strains against
COVID-19 (SARS-CoV-2)⁵

DNA plasmid neither replicates nor triggers any vector
directed immune response in vaccinated individuals
as it contains non replicating bacterial DNA plasmid
backbone in addition to being devoid of any live virus
particles^9,10

ZyCoV-D^® Important Reminders

What should you mention to your healthcare provider before you get ZyCoV-D® vaccine?

Tell the healthcare provider about all of your medical conditions, including:

If you have ever had a severe allergic reaction (anaphylaxis) after any drug, food, any vaccine or any ingredients of ZyCoV-D^® vaccine
If you have fever
If you have a bleeding disorder or are on a blood thinner
If you are immunocompromised or are on a medicine that affects your immune system
If you are pregnant or plan to become pregnant
If you are breastfeeding
If you have received another COVID-19 vaccine

You should consult your healthcare provider before deciding to take the vaccine.

Who should not get ZyCoV-D® vaccine?

You should not get ZyCoV-D^® vaccine if you:

Had a severe allergic reaction after a previous dose of this vaccine
Had a severe allergic reaction to any ingredient of this vaccine
Had a severe allergic reaction to any other vaccine

What are the benefits of ZyCoV-D® vaccine?

In ongoing clinical trials, ZyCoV-D^® vaccine has been shown to prevent covid-19 disease following 3 doses of 2mg each given 28 days apart. The duration of protection against COVID-19 disease is currently unknown. You may get protective immune response 28 days after the 3rd dose of ZyCoV-D^® vaccine.

The world’s first needle-free vaccine for COVID-19

ZyCoV-D^® How it works

ZyCoV-D^® vaccine comprises of a DNA plasmid vector carrying region expressing SARS-CoV-2 spike(S) protein.¹³

Plasmid DNA are circular DNA  that are found only in  bacteria. These are different from the DNA present in our cells.  This means that plasmid DNA  cannot be inherited or passed on from one generation to another, unlike  the DNA  found in our cells. Researchers can insert DNA fragments or genes into a plasmid vector, creating a so-called recombinant plasmid.^{9, 10}